Introduction to BOIN: The Effective, Flexible and Transparent Phase I Clinical Trial Design

Поделиться
HTML-код
  • Опубликовано: 27 янв 2025

Комментарии • 4

  • @SajiSNairNair-tu9dk
    @SajiSNairNair-tu9dk 4 месяца назад

    👉unknow 🤗😊😂

  • @79code
    @79code Год назад

    Please confirm that last part. Did you mean which of the 3 candidate MTDs is most effective? or did you mean which can be an overall MTD (uber MTD)? Since there isn't any effective/efficacy stuff yet.

    • @alysestaley
      @alysestaley Год назад +1

      We are selecting one dose to be the MTD. The MTD is the dose level (candidate MTD) that has an observed toxicity rate closest to the pre-specified target DLT rate. The observed toxicity rate is estimated with isotonic regression. Hope that helps!

    • @79code
      @79code Год назад +1

      @@alysestaley yes it does. Thanks much. Very nice presentation. I wish I knew about boin much earlier.